F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance

Table 1 The association between F-box protein 22 expression and clinicopathological characteristics, n (%)

Pathological trait	Number of cases	Expression of FBXO22		χ2	P value
		High (n = 55)	Low (n = 18)
Age				0.003	0.957
≥ 60	28	21 (38.18)	7 (38.89)
< 60	45	34 (61.82)	11 (61.11)
Gender				0.125	0.724
Male	42	31 (56.36)	11 (61.11)
Female	31	24 (43.64)	7 (38.89)
BMI				0.408	0.523
≥ 25 kg/m2	29	23 (41.82)	6 (33.33)
< 25 kg/m2	44	32 (58.18)	12 (66.67)
Educational background				0.054	0.816
High school and above	26	20 (36.36)	6 (33.33)
Junior high school and below	47	35 (63.64)	12 (66.67)
Tumor stages				6.508	0.011
I-II	42	27 (49.09)	15 (83.33)
III-IV	31	28 (50.91)	3 (16.67)
Lymph node metastasis				10.392	0.001
Yes	32	30 (54.55)	2 (22.11)
No	41	25 (45.45)	16 (88.89)
Degree of differentiation				5.890	0.015
Low	30	27 (49.09)	3 (16.67)
Middle and high	43	28 (50.91)	15 (83.33)
Diameter of the tumour				6.334	0.012
≥ 3 cm	35	31 (56.36)	4 (22.22)
< 3 cm	38	24 (43.64)	14 (77.78)
Smoking history				1.853	0.173
Yes	50	40 (72.73)	10 (55.56)
No	23	15 (27.27)	8 (44.44)
Drinking history				0.003	0.957
Yes	45	34 (61.82)	11 (61.11)
No	28	21 (38.18)	7 (38.89)

FBXO22: F-box protein 22.